Effects of Sorafenib on C-Terminally Truncated Androgen Receptor Variants in Human Prostate Cancer Cells
暂无分享,去创建一个
[1] S. Ellard,et al. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer , 2012, Investigational New Drugs.
[2] H. Inui,et al. Androgen deprivation causes truncation of the C‐terminal region of androgen receptor in human prostate cancer LNCaP cells , 2012, Cancer science.
[3] P. Nelson,et al. The androgen/androgen receptor axis in prostate cancer , 2012, Current opinion in oncology.
[4] Yingming Li,et al. Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal* , 2012, The Journal of Biological Chemistry.
[5] Daniel Gioeli,et al. Post-translational modification of the androgen receptor , 2012, Molecular and Cellular Endocrinology.
[6] A. Hobisch,et al. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways , 2012, Endocrine-related cancer.
[7] K. Spindler,et al. IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. , 2012, Neoplasia.
[8] M. Höpfner,et al. AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells , 2012, World Journal of Urology.
[9] P. Nelson,et al. Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases , 2011, PloS one.
[10] M. Cronauer,et al. Inhibition of Glycogen Synthase Kinase-3β Counteracts Ligand-Independent Activity of the Androgen Receptor in Castration Resistant Prostate Cancer , 2011, PloS one.
[11] P. Nelson,et al. Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.
[12] M. Sadar,et al. Androgen receptor and its splice variants in prostate cancer , 2011, Cellular and Molecular Life Sciences.
[13] N. Socci,et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.
[14] D. Grandér,et al. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. , 2010, International journal of oncology.
[15] H. Zeng,et al. The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. , 2010, Asian journal of andrology.
[16] M. Cronauer,et al. Inhibition of glycogen synthase kinase‐3β promotes nuclear export of the androgen receptor through a CRM1‐dependent mechanism in prostate cancer cell lines , 2010, Journal of cellular biochemistry.
[17] G. Sonpavde,et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] S. Steinberg,et al. Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer , 2009, BJU international.
[19] P. Kantoff,et al. Phase II study of sunitinib in men with advanced prostate cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] X. Liu,et al. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. , 2008, Molecular endocrinology.
[21] M. Gleave,et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.
[22] R. Hautmann,et al. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? , 2008, Neoplasia.
[23] S. Steinberg,et al. A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.
[24] D. Strumberg,et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV , 2007, British Journal of Cancer.
[25] P. Thall,et al. Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases , 2007, Clinical Cancer Research.
[26] C. Tepper,et al. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. , 2007, Cancer research.
[27] N. Moore,et al. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. , 2007, Molecular endocrinology.
[28] D. Jacqmin,et al. Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation—A new paradigm for cooperation among prostate tumor cells , 2007, International journal of cancer.
[29] C. Suschek,et al. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression , 2007, Oncogene.
[30] G. Bubley,et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1 , 2006, Proceedings of the National Academy of Sciences.
[31] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[32] J. Moul,et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.
[33] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[34] A. Armstrong,et al. Dasatinib combined with docetaxel for castration‐resistant prostate cancer , 2012, Cancer.
[35] A. Jemal,et al. Global Cancer Statistics , 2011 .
[36] M. Safarinejad. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study. , 2010, Urologic oncology.
[37] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[38] L. Seymour,et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] D. Chopin,et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: A new mechanism for androgen‐independent growth in prostate cancer , 2004, International journal of cancer.
[40] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[41] P. Stattin,et al. Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.